Log In
Print
BCIQ
Print
Print this Print this
 

Janumet XR, sitagliptin/metformin

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFixed-dose combination of Januvia sitagliptin phosphate plus extended-release metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26) ; AMP-activated protein kinase (AMPK)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today